# A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies

Source: https://onco.cc/trials/nct05908409/  
OnCo record `nct05908409` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of IDP-121 in multiple myeloma, diffuse large B-cell lymphoma, non-Hodgkin lymphoma and chronic lymphocytic leukaemia, run by IDP Discovery Pharma S.L., now recruiting.

## Summary

A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies is a phase 1/2 interventional study registered as NCT05908409 by IDP Discovery Pharma S.L., with 37 participants planned, started 2023-06-05 and due to reach its primary completion in 2025-12-22. Interventions recorded: IDP-121.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05908409
- Phase: 1/2
- Setting: A Phase 1/2 Multicenter, Open-label, Dose-escalation Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies (CASSANDRA)
- Sponsor: IDP Discovery Pharma S.L.
- Enrolled: 37

## Sources

- ClinicalTrials.gov NCT05908409: https://clinicaltrials.gov/study/NCT05908409

## Connected records

- cancers: [Chronic lymphocytic leukaemia](https://onco.cc/cancers/cll/), [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/), [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)

---
JSON: https://onco.cc/api/v1/entities/nct05908409.json